Heron Therapeutics Announces Appointment of Thomas Cusack to Board of DirectorsCARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025.
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights.
